103241Establishing Commercial AAV Manufacturing in the UKClosedCollaborative R&DInnovate UKNightstaRx (NSR) is a biotechnology company whose mission is to restore and maintain sight by developing novel gene therapies to treat rare, degenerative diseases causing blindness. NSR are applying for this grant, in conjunction with a partner, Cell & Gene Therapy Catapult, to expedite the development of a treatment for an inherited blindness disease called Retinitis Pigmentosa. CGT are an organisation who have the scientific expertise and accredited laboratories to help NSR complete the development of a state of the art manufacturing process to make this treatment. The result of this project will mean NSR will be able to treat patients to help improve their quality of life and keep their independence. Establishment of this type of manufacturing process would not only make manufacturing of other similar products easier, but also help put the UK in a position to be a first in class global manufacturer of viral gene therapies for late stage clinical & commercial supply. In turn it would also increase the skilled workforce and create jobs. All of these benefits will result in each company increasing their revenues, which will contribute to making the UK economy stronger.